Karvedilol etkileşimleri

Should not be used in combination with other alpha adrenergic antagonists ( 5.4 , 7.2 ) (Alfuzosin etiketi, Uyarılar ve önlemler)

Do not use JALYN with other alpha-adrenergic antagonists, as this may increase the risk of hypotension. (Dutasterid ve tamsulosin etiketi, Uyarılar ve önlemler)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (Eptifibatid etiketi, Kontrendikasyonlar)

Concomitant negative chronotropic therapy such as digoxin or beta-blockers may lower the risk of this complication. (Flekainid etiketi, Kutulu uyarı)

Avoid coadministration of FANAPT with alpha-adrenergic blocking agents and adjust medications that affect blood pressure as needed [see Warnings and Precautions (5.7) ] . (İloperidon etiketi, İlaç etkileşimleri)

…that Affect Concomitant Drug Concentrations Concomitant Drug Within Class Prevention or Management Drug Interactions with TOLSURA that Increase Concomitant Drug Concentrations and May Increase Risk of Adverse Reactions Associated with the Concomitant Drug Alpha Blockers Alfuzosin Silodosin Tamsulosin Not recommended during and 2 weeks after TOLSURA treatment. (İtrakonazol etiketi, İlaç etkileşimleri)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (Klozapin etiketi, Kutulu uyarı)

In addition, life-threatening arrhythmias may occur during anesthesia and surgery, and may require treatment with a beta-blocker or lidocaine. (Metirozin etiketi, Uyarılar)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (Metolazon etiketi, Uyarılar)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (Minoksidil etiketi, Kutulu uyarı)

Hypotensive Agents Do not use BYSTOLIC with other β-blockers. (Nebivolol etiketi, İlaç etkileşimleri)

Risk factors include high dose or overdose, rapid administration (see WARNINGS and DOSAGE AND ADMINISTRATION ), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers). (Protamin etiketi, Kutulu uyarı)

Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 ) (Repaglinid etiketi, İlaç etkileşimleri)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (Rivastigmin etiketi, İlaç etkileşimleri)

Silodosin capsules should not be used in combination with other alpha-blockers. (Silodosin etiketi, Uyarılar ve önlemler)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (Tadalafil etiketi, Uyarılar ve önlemler)

Effect of Other Drugs on TALZENNA Effect of P-gp Inhibitors Breast Cancer Avoid coadministration of TALZENNA with the following P-gp inhibitors: itraconazole, amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil. (Talazoparib etiketi, İlaç etkileşimleri)

• Should not be used in combination with other alpha adrenergic blocking agents ( 5.2 , 7.2 , 12.3 ) (Tamsulosin etiketi, Uyarılar ve önlemler)

…Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension e Blood glucose-lowering… (Tranilsipromin etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone may increase carvedilol levels resulting in further slowing of the heart rate or cardiac conduction. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Beta-blockers may decrease effectiveness. (Arformoterol etiketi, İlaç etkileşimleri)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (Aripiprazol etiketi, İlaç etkileşimleri)

There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (Armodafinil etiketi, Uyarılar ve önlemler)

Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Asenapin etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Beta Blockers The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow and salt and fluid retention. (Aspirin ve dipiridamol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (Atomoksetin etiketi, İlaç etkileşimleri)

• Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (Avanafil etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Amphetamines may decrease the hypotensive effect of antihypertensives. (Benzfetamin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Brekspiprazol etiketi, Uyarılar ve önlemler)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (Brimonidin etiketi, İlaç etkileşimleri)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Karvedilol etiketi, İlaç etkileşimleri)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (Bromfeniramin, psödoefedrin ve dekstrometorfan etiketi, İlaç etkileşimleri)

Use caution in patients taking antihypertensive medications. (Bromokriptin etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Budesonid ve formoterol etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Risk of Hypertension and Bradycardia Due to Drug Interactions Between MARCAINE WITH EPINEPHRINE and Nonselective Beta-Adrenergic Antagonists Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. (Bupivakain etiketi, Uyarılar ve önlemler)

Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Examples: Ramipril, captopril Beta Blockers Clinical Impact: The hypotensive effects of beta blockers may be diminished by the concomitant administration of aspirin due to inhibition of renal prostaglandins, leading to decreased renal blood flow, and salt and fluid retention. (Butalbital, aspirin, kafein ve kodein etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

• Antihypertensive Drugs: Monitor blood pressure. (Deksmetilfenidat etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (Dietilpropion etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Cyclosporine or digoxin levels may increase. (Karvedilol etiketi, İlaç etkileşimleri)

Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of Dihydroergotamine Mesylate Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. (Dihidroergotamin etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of ZIPSOR and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Diklofenak etiketi, İlaç etkileşimleri)

• During concomitant use of diclofenac sodium/misoprostol and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Diklofenak ve misoprostol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (Dofetilid etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Karvedilol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Give a low dose of beta-blockers initially, and increase only after ECG verification of good tolerability [see Drug Interactions (7.3) , Clinical Pharmacology (12.3) ] . (Dronedaron etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (Epoetin alfa etiketi, Uyarılar ve önlemler)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (Epoprostenol etiketi, İlaç etkileşimleri)

The beta-blocker Inderal (propranolol) has been reported to potentiate the vasoconstrictive action of ergotamine tartrate and caffeine tablets by blocking the vasodilating property of epinephrine. (Ergotamin ve kafein etiketi, İlaç etkileşimleri)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Karvedilol etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of FENOPROFEN CALCIUM with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects [ see Warnings and Precautions ( 5.6 ) ]. (Fenoprofen etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of flurbiprofen and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Flurbiprofen etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Propranolol and Other Beta-Blockers: Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. (Fluvoksamin etiketi, İlaç etkileşimleri)

• Beta-blockers may decrease effectiveness. (Formoterol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Table 4: Clinically Significant Drug Interaction with GVOKE and GVOKE VialDx Beta-Blockers Clincial Impact: Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given GVOKE or GVOKE VialDx. (Glukagon etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

During concomitant use of hydrocodone bitartrate and ibuprofen tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Hidrokodon ve ibuprofen etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of CALDOLOR and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (İbuprofen etiketi, İlaç etkileşimleri)

Intervention: During concomitant use of ibuprofen and famotidine tablet and ACE-inhibitors, ARBs, or beta- blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (İbuprofen ve famotidin etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of INDOCIN and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (İndometazin etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). (İvabradin etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (Karbidopa etiketi, İlaç etkileşimleri)

Antihypertensive drugs: May cause symptomatic postural hypotension. (Karbidopa ve levodopa etiketi, İlaç etkileşimleri)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (Karbidopa, levodopa ve entakapon etiketi, İlaç etkileşimleri)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (Kariprazin etiketi, Uyarılar ve önlemler)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ketiapin etiketi, Uyarılar ve önlemler)

Alpha Blockers tamsulosin Analgesics methadone alfentanil, buprenorphine IV and sublingual, fentanyl, oxycodone, sufentanil Methadone: The potential increase in plasma concentrations of methadone when coadministered with ketoconazole tablets may increase the risk of serious cardiovascular events including QT prolongation and torsade de pointes, or respiratory… (Ketokonazol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (Lakozamid etiketi, Uyarılar ve önlemler)

Bradycardia-Inducing Drugs (e.g., beta-blockers) : Lanreotide Injection may decrease heart rate. (Lanreotid etiketi, İlaç etkileşimleri)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease, may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Ledipasvir ve sofosbuvir etiketi, Uyarılar ve önlemler)

In this setting, cardioselective beta-blockers should be considered, although they should be administered with caution. (Levosalbutamol etiketi, İlaç etkileşimleri)

Drug or Drug Class Effect Beta-adrenergic antagonists e.g., Propranolol > 160 mg/day) In patients treated with large doses of propranolol (> 160 mg/day), T 3 and T 4 levels change slightly, TSH levels remain normal, and patients are clinically euthyroid. (Levotiroksin etiketi, İlaç etkileşimleri)

Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Drug or Drug Class Effect Beta-adrenergic antagonists (e.g., Propranolol >160 mg/day) In patients treated with large doses of propranolol (>160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. (Liyotironin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (Lumateperon etiketi, Uyarılar ve önlemler)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (Lurasidon etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of mefenamic acid and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Mefenamik asit etiketi, İlaç etkileşimleri)

There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a beta blocker (propranolol) (see PRECAUTIONS, Cardiac Effects ). (Meflokin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of QAMZOVA and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Meloksikam etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Beta-blockers Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. (Metilergometrin etiketi, İlaç etkileşimleri)

Antihypertensive Drugs: Monitor blood pressure. (Metilfenidat etiketi, İlaç etkileşimleri)

…(oral): Due to potential inhibition of vitamin K activity by methimazole, the activity of oral anticoagulants (e.g., warfarin) may be increased; additional monitoring of PT/INR should be considered, especially before surgical procedures. β-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. (Metimazol etiketi, İlaç etkileşimleri)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (Mirtazapin etiketi, Uyarılar ve önlemler)

However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (Modafinil etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Patients receiving concomitant negative chronotropic drugs (e.g., beta blockers) may be more at risk for hypotension in case of hypersensitivity reaction. (Motiksafortid etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

( 5.3 Hepatotoxicity) Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Naproksen etiketi, Uyarılar ve önlemler)

Intervention : • During concomitant use of naproxen and esomeprazole magnesium delayed-release tablets and ACE-inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Naproksen ve esomeprazol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (Niasin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Antihypertensives: Possible additive hypotensive effects. (Nitrogliserin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Intervention: During concomitant use of OXAPROZIN CAPSULES and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Oksaprozin etiketi, İlaç etkileşimleri)

Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. (Oksimetazolin etiketi, İlaç etkileşimleri)

Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Oktreotid etiketi, Uyarılar ve önlemler)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (Olanzapin etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (Paliperidon etiketi, Uyarılar ve önlemler)

• Hypertension : Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs. (Parasetamol ve ibuprofen etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (Pasireotid etiketi, Uyarılar ve önlemler)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (Pazopanib etiketi, Uyarılar ve önlemler)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (Pentoksifilin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Drug Interactions Pilocarpine should be administered with caution to patients taking beta-adrenergic antagonists because of the possibility of conduction disturbances. (Pilokarpin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (Piridostigmin etiketi, Uyarılar ve önlemler)

Monitor patients to assure diuretic efficacy including antihypertensive effects (7) (Piroksikam etiketi, İlaç etkileşimleri)

Experience with PONVORY is limited in patients receiving concurrent therapy with drugs that decrease heart rate (e.g., beta-blockers, non-dihydropyridine calcium channel blockers - diltiazem and verapamil, and other drugs that may decrease heart rate such as digoxin). (Ponesimod etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Such patients may be unresponsive to the usual doses of epinephrine used to treat allergic reaction. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Beta-adrenergic blocking agents: Hyperthyroidism may cause an increased clearance of beta blockers with a high extraction ratio. (Propiltiourasil etiketi, İlaç etkileşimleri)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

CYP P450 2D6 enzyme inhibitors may increase and rifampin may decrease carvedilol levels. (Karvedilol etiketi, İlaç etkileşimleri)

…Anticonvulsants Phenytoin Antimalarials Quinine Azole Antifungals Fluconazole, itraconazole, ketoconazole Antipsychotics Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics… (Rifapentin etiketi, İlaç etkileşimleri)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (Riosiguat etiketi, Uyarılar ve önlemler)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (Risperidon etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. (Ropivakain etiketi, Uyarılar ve önlemler)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Beta-blockers: Use with caution. (Salbutamol etiketi, İlaç etkileşimleri)

• Beta-blockers: Use with caution. (Salmeterol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

Intervention: • During concomitant use of VYSCOXA and ACE inhibitors, ARBs, or beta-blockers, monitor blood pressure to ensure that the desired blood pressure is obtained. (Selekoksib etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

DRUG INTERACTIONS Cevimeline should be administered with caution to patients taking beta adrenergic antagonists, because of the possibility of conduction disturbances. (Sevimelin etiketi, İlaç etkileşimleri)

Anesthesia If treatment with COREG is to be continued perioperatively, particular care should be taken when anesthetic agents that depress myocardial function, such as ether, cyclopropane, and trichloroethylene, are used [see Overdosage (10) ]. (Karvedilol etiketi, İlaç etkileşimleri)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (Siklobenzaprin etiketi, İlaç etkileşimleri)

Cyclosporine or digoxin levels may increase. (Karvedilol etiketi, İlaç etkileşimleri)

Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (Sildenafil etiketi, Uyarılar ve önlemler)

Cimetidine increased AUC by about 30% but caused no change in C max [see Clinical Pharmacology (12.5) ] . (Karvedilol etiketi, İlaç etkileşimleri)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

Patients also taking beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease may be at increased risk for symptomatic bradycardia with coadministration of amiodarone. (Sofosbuvir ve velpatasvir etiketi, Uyarılar ve önlemler)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (Sorafenib etiketi, Uyarılar ve önlemler)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Karvedilol etiketi, İlaç etkileşimleri)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Monitor patients to assure diuretic efficacy including antihypertensive effects. (Sumatriptan ve naproksen etiketi, İlaç etkileşimleri)

Initiate and/or adjust antihypertensive therapy as appropriate. (Sunitinib etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

• Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (Takrolimus etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

CYP2D6 Inhibitors and Poor Metabolizers Interactions of carvedilol with potent inhibitors of CYP2D6 isoenzyme (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol [see Clinical Pharmacology (12.3) ]. (Karvedilol etiketi, İlaç etkileşimleri)

In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. (Terbutalin etiketi, Önlemler)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (Testosteron etiketi, Uyarılar ve önlemler)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

As with other β-blockers, if COREG is administered with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored. (Karvedilol etiketi, İlaç etkileşimleri)

Insulin and oral hypoglycemics action may be enhanced. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (Trazodon etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Use of BCRP and/or P-gp only inhibitors (e.g., quinidine, carvedilol, eltrombopag, curcumin) may increase the exposure of ubrogepant [ s ee Clinical Pharmacology ( 12.3 ) ] . (Ubrogepant etiketi, İlaç etkileşimleri)

• Beta-blockers: Use with caution. (Umeklidinyum ve vilanterol etiketi, İlaç etkileşimleri)

Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. (Karvedilol etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (Karvedilol etiketi, Uyarılar ve önlemler)

Alpha-Blockers : Caution is advised when PDE5 inhibitors are co-administered with alpha-blockers. (Vardenafil etiketi, Uyarılar ve önlemler)

Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (Venlafaksin etiketi, İlaç etkileşimleri)

COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (Karvedilol etiketi, Uyarılar ve önlemler)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (Karvedilol etiketi, İlaç etkileşimleri)

Zileuton increases propranolol levels and beta-blocker activity. (Zileuton etiketi, İlaç etkileşimleri)

Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (Ziprasidon etiketi, Uyarılar ve önlemler)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (Adenozin etiketi, İlaç etkileşimleri)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (Butorfanol etiketi, Uyarılar)

Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (Dekstroamfetamin etiketi, İlaç etkileşimleri)

This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (Desipramin etiketi, Uyarılar)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (Desogestrel ve etinilestradiol etiketi, Uyarılar)

Drug Interactions ACE-inhibitors and Angiotensin II Anagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Diflunisal etiketi, İlaç etkileşimleri)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (Efedrin etiketi, İlaç etkileşimleri)

Drug Interactions ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Etodolak etiketi, İlaç etkileşimleri)

Tachycardia and cardiac arrhythmiasmay occur with the use of phentolamine or other alpha-adrenergic blocking agents. (Fentolamin etiketi, Uyarılar ve önlemler)

…PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines,… (Finasterid etiketi, İlaç etkileşimleri)

Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem) Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or AV conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers, such as diltiazem or verapamil) is limited. (Fingolimod etiketi, İlaç etkileşimleri)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (İkatibant etiketi, İlaç etkileşimleri)

CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (Karbamazepin etiketi, İlaç etkileşimleri)

ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Ketoprofen etiketi, Uyarılar ve önlemler)

Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. (Ketorolak etiketi, İlaç etkileşimleri)

Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (Klorpromazin etiketi, Uyarılar)

Effects on the absorption of other beta-blockers have not been determined. (Kolestipol etiketi, İlaç etkileşimleri)

Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (Karvedilol etiketi, Uyarılar ve önlemler)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (Meksiletin etiketi, İlaç etkileşimleri)

Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of midodrine hydrochloride. (Midodrin etiketi, İlaç etkileşimleri)

Drug Interactions: ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Nabumeton etiketi, İlaç etkileşimleri)

The antihypertensive action of guanethidine and similar agents may be blocked. (Nortriptilin etiketi, Uyarılar)

Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, β-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). (Perfenazin etiketi, İlaç etkileşimleri)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (Proklorperazin etiketi, Önlemler)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (Protriptilin etiketi, Uyarılar)

DRUG INTERACTIONS ACE-inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. (Salsalat etiketi, İlaç etkileşimleri)

Drug Interactions ACE-Inhibitors and Angiotensin II Antagonists Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors and angiotensin II antagonists. (Sulindak etiketi, İlaç etkileşimleri)

Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (Karvedilol etiketi, Uyarılar ve önlemler)

DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. (Tolmetin etiketi, İlaç etkileşimleri)

Angiotensin Receptor Blockers, Angiotensin Converting Enzyme Inhibitors and Potassium Sparing Diuretics Although specific interaction studies were not performed, in clinical studies, tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. (Tolvaptan etiketi, İlaç etkileşimleri)

Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (Trifluoperazin etiketi, Önlemler)

Alpha-adrenergic Antagonists The administration of dutasteride capsules in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. (Dutasterid etiketi, İlaç etkileşimleri)

Beta-adrenergic blocking agents: Coadministration of beta-adrenergic blocking agents did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (İbutilid etiketi, İlaç etkileşimleri)